Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / AIM - AIM ImmunoTech' Ampligen an Orphan Drug in U.S. for the treatment of pancreatic cancer

AIM - AIM ImmunoTech' Ampligen an Orphan Drug in U.S. for the treatment of pancreatic cancer

AIM ImmunoTech Inc.
The FDA grants Orphan Drug designation to AIM ImmunoTech' (AIM) drug Ampligen (rintatolimod) for the treatment of pancreatic cancer.The Orphan Drug tag may provide incentivize the treatment of therapies to treat unmet medical needs by providing a company with seven years of exclusivity rights once a drug reaches market.Previously in Sep.20,  AIM announced positive results from an Ampligen multiyear early access program in the Netherlands for pancreatic cancer patients.

For further details see:

AIM ImmunoTech' Ampligen an Orphan Drug in U.S. for the treatment of pancreatic cancer
Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...